Werewolf Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Werewolf Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.82M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($70.52M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($37.37M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($53.81M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($49.98M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($15.04M) | Mar 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.68M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($73.59M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($40.50M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($56.06M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($50.09M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($22.40M) | Mar 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.83M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $56.43M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $41.78M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $53.76M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $35.27M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $16.64M | Mar 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.29M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($56.19M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($32.61M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($40.60M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($42.88M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($18.62M) | Mar 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $254.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $769.0K | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $3.61M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $498.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $560.0K | Mar 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.40M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $126.93M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $174.83M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $160.25M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $179.25M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $96.40M | Mar 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.59M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $53.54M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $63.46M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $37.91M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $26.46M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.18M | Mar 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.81M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $73.39M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $111.37M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $122.34M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $152.79M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($51.86M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($24.30M) | Mar 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($475.41M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($414.59M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($344.07M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($306.71M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($252.90M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($51.87M) | Mar 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.05M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $111.00M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $134.34M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $129.32M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $157.53M | Mar 23, 2023 |
| FY2022 | Dec 31, 2020 | $92.57M | Mar 23, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.09M | Mar 27, 2026 |
| FY2024 | Dec 31, 2024 | $32.09M | Mar 11, 2025 |
| FY2023 | Dec 31, 2023 | $40.00M | Mar 7, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (10) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (28) | Mar 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (10) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (28) | Mar 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.60M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 44.83M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 39.11M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 31.43M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 27.31M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 1.18M | Mar 24, 2022 |